Key result
Rivaroxaban treats and prevents VTE while reducing stroke risk in non-valvular AF.
News - SA Heart Journal 2016.
No takes yet. Share an insight, caveat, or question.
Bayer Pharmaceuticals (2016) studied Thromboembolic disorders (VTE, SPAF, DVT, PE). Rivaroxaban was evaluated. Rivaroxaban is a non-vitamin K oral anticoagulant indicated for the prevention and treatment of venous thromboembolism, deep vein thrombosis, pulmonary embolism, and stroke in non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: